Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INCA033989 + ruxolitinib
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
INCA033989 + ruxolitinib is an investigational combination therapy being studied for the treatment of myeloproliferative neoplasms, including myelofibrosis and essential thrombocythemia. INCA033989 is a drug candidate targeting a novel disease pathway (precise molecular target not disclosed in public sources), and ruxolitinib is an approved oral Janus kinase (JAK1 and JAK2) inhibitor that modulates cytokine signaling and hematopoiesis. Ruxolitinib is approved for the treatment of myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease. The rationale for the combination is that INCA033989, when added to ruxolitinib, may provide enhanced therapeutic efficacy via complementary inhibition of the JAK-STAT pathway and additional mechanisms relevant to disease pathology. This combination is currently being evaluated in phase 1/2 clinical trials to determine safety, tolerability, and optimal dosing in patients with myeloproliferative neoplasms who may have had a suboptimal response to ruxolitinib alone[1][3][5][7].
- Brand names
- Jakavi
- Other names
- INCA033989 + ruxolitinib
02
Targets
Beyond the preview
Go deeper on INCA033989 + ruxolitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INCA033989 + ruxolitinib.